962 related articles for article (PubMed ID: 26091818)
1. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N
Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818
[TBL] [Abstract][Full Text] [Related]
2. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
3. Donepezil for mild cognitive impairment.
Birks J; Flicker L
Cochrane Database Syst Rev; 2006 Jul; (3):CD006104. PubMed ID: 16856114
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for vascular cognitive impairment.
Birks J; McGuinness B; Craig D
Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
[TBL] [Abstract][Full Text] [Related]
5. Galantamine for vascular cognitive impairment.
Birks J; Craig D
Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
[TBL] [Abstract][Full Text] [Related]
6. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
[TBL] [Abstract][Full Text] [Related]
7. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Dubois B; Chupin M; Hampel H; Lista S; Cavedo E; Croisile B; Louis Tisserand G; Touchon J; Bonafe A; Ousset PJ; Ait Ameur A; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Delmaire C; Ceccaldi M; Girard N; Dufouil C; Lehericy S; Tonelli I; Duveau F; Colliot O; Garnero L; Sarazin M; Dormont D; ;
Alzheimers Dement; 2015 Sep; 11(9):1041-9. PubMed ID: 25596420
[TBL] [Abstract][Full Text] [Related]
8. The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis.
Cui CC; Sun Y; Wang XY; Zhang Y; Xing Y
Medicine (Baltimore); 2019 Jul; 98(27):e16091. PubMed ID: 31277107
[TBL] [Abstract][Full Text] [Related]
9. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
[TBL] [Abstract][Full Text] [Related]
10. Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Matsunaga S; Kishi T; Annas P; Basun H; Hampel H; Iwata N
J Alzheimers Dis; 2015; 48(2):403-10. PubMed ID: 26402004
[TBL] [Abstract][Full Text] [Related]
11. WITHDRAWN: Tacrine for Alzheimer's disease.
Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
[TBL] [Abstract][Full Text] [Related]
12. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
13. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.
Kishi T; Ikuta T; Oya K; Matsunaga S; Matsuda Y; Iwata N
Int J Neuropsychopharmacol; 2018 Aug; 21(8):748-757. PubMed ID: 29762677
[TBL] [Abstract][Full Text] [Related]
14. Nimodipine for primary degenerative, mixed and vascular dementia.
López-Arrieta JM; Birks J
Cochrane Database Syst Rev; 2002; (3):CD000147. PubMed ID: 12137606
[TBL] [Abstract][Full Text] [Related]
15. Vitamin E for Alzheimer's disease and mild cognitive impairment.
Isaac MG; Quinn R; Tabet N
Cochrane Database Syst Rev; 2008 Jul; (3):CD002854. PubMed ID: 18646084
[TBL] [Abstract][Full Text] [Related]
16. Nimodipine for primary degenerative, mixed and vascular dementia.
López-Arrieta ; Birks J
Cochrane Database Syst Rev; 2001; (1):CD000147. PubMed ID: 11279679
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
[TBL] [Abstract][Full Text] [Related]
18. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
19. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]